ArticleTranslational vision science & technology2025
Efficacy of Subconjunctivally Applied Everolimus- and Sirolimus-Pretreated MSCs in Preventing Diabetic Retinopathy.
Article in Translational vision science & technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrating bioinformatic prediction and the "gut microbiota-inflammation-skin axis" to decipher the mechanisms of quercetin (fromFrontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Diabetic retinopathy (DR) is a leading cause of vision impairment in diabetic patients. This study investigates the preventive effects of subconjunctivally applied mesenchymal stem cells (MSCs) pretreated with mammalian target of rapamycin (mTOR) inhibitors on DR. Methods: Thirty-six male Sprague-Dawley rats were used, with diabetes induced by a single intraperitoneal injection of streptozotocin (STZ) at 55 mg/kg. Four groups were established: diabetic control, MSC-treated, everolimus-pretreated MSC-treated (MSC-E), and sirolimus-pretreated MSC-treated (MSC-S). Each treated group received subconjunctival injections of 1 × 106 MSCs in 30 µL phosphate-buffered saline at 3, 5, and 7 weeks post-STZ. Electroretinography (ERG) was performed at 2 and 8 weeks post-STZ. At 11 weeks, cataract formation, uveitis grading, and retinal histology were assessed. Results: mTOR inhibitor-pretreated MSCs significantly prevented the decline in retinal function compared to untreated MSCs and diabetic controls. Everolimus-pretreated MSCs tended to show higher ERG flicker amplitudes than sirolimus-pretreated MSCs, although the difference was not statistically significant. Histologically, both pretreated groups showed preserved thickness in the outer plexiform and nuclear layers, suggesting protection against retinal damage. Conclusions: Subconjunctival application of MSCs pretreated with mTOR inhibitors may help prevent DR progression, with everolimus showing a potential advantage in preserving retinal function. Translational Relevance: These findings suggest that mTOR inhibitor-pretreated MSCs could be a viable therapeutic strategy for DR, warranting further clinical trials to confirm efficacy and safety in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.